Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608926 | 1.00 | ACE (0.44) | ACELMNASMN1; SMN2MTNR1BRORC | |
| SCHEMBL3607354 | 0.82 | ACE (0.46) | ACELMNASMN1; SMN2MTNR1BRORC | |
| SCHEMBL3607627 | 0.81 | ACE (0.47) | ACELMNASMN1; SMN2MTNR1BRORC | |
| SCHEMBL3617469 | 0.79 | ACE (0.43) | ACEMTNR1BRORCXIAPF11 | |
| SCHEMBL3612165 | 0.79 | ACE (0.50) | ACEMTNR1B | |
| SCHEMBL3604048 | 0.79 | XIAP (0.49) | ACEMTNR1BXIAP | |
| SCHEMBL3603946 | 0.79 | SMN1; SMN2 (0.45) | LMNASMN1; SMN2MEN1KMT2AXIAP | |
| SCHEMBL3609218 | 0.78 | ACE (0.70) | ACEMTNR1B | |
| SCHEMBL3604484 | 0.76 | RORC (0.45) | ACEMTNR1BRORCKMT2AXIAP | |
| SCHEMBL3605252 | 0.76 | GAA (0.49) | ACEMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | KCNN3, KCNN2, KCNN1 | ACE 2202/4885LMNA 2021/4885SMN1; SMN2 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.